D
Douglas T. Fearon
Researcher at Cold Spring Harbor Laboratory
Publications - 284
Citations - 40110
Douglas T. Fearon is an academic researcher from Cold Spring Harbor Laboratory. The author has contributed to research in topics: Complement system & Receptor. The author has an hindex of 94, co-authored 278 publications receiving 35140 citations. Previous affiliations of Douglas T. Fearon include Harvard University & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
The instructive role of innate immunity in the acquired immune response.
TL;DR: Innate immunity has been considered only to provide rapid, incomplete antimicrobial host defense until the slower, more definitive acquired immune response develops but may have an additional role in determining which antigens the acquired immune system responds to and the nature of that response.
Journal ArticleDOI
A framework for advancing our understanding of cancer-associated fibroblasts
Erik Sahai,Igor Astsaturov,Edna Cukierman,David G. DeNardo,Mikala Egeblad,Ronald M. Evans,Ronald M. Evans,Douglas T. Fearon,Douglas T. Fearon,Florian R. Greten,Sunil R. Hingorani,Tony Hunter,Richard O. Hynes,Rakesh K. Jain,Tobias Janowitz,Claus Jørgensen,Alec C. Kimmelman,Mikhail G. Kolonin,Robert G. Maki,Robert G. Maki,R. Scott Powers,Ellen Puré,Daniel C. Ramirez,Ruth Scherz-Shouval,Mara H. Sherman,Sheila A. Stewart,Thea D. Tlsty,David A. Tuveson,Fiona M. Watt,Valerie M. Weaver,Ashani T. Weeraratna,Zena Werb +31 more
TL;DR: This Consensus Statement issues a call to action for all cancer researchers to standardize assays and report metadata in studies of cancer-associated fibroblasts to advance the understanding of this important cell type in the tumour microenvironment.
Journal ArticleDOI
T cell exclusion, immune privilege, and the tumor microenvironment
TL;DR: Evidence is reviewed that stromal cells of the tumor microenvironment mediate this restriction by excluding T cells from the vicinity of cancer cells, and overcoming this T cell checkpoint may enable optimal immunotherapy.
Journal ArticleDOI
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Christine Feig,James O. Jones,Matthew Kraman,Richard J.B. Wells,Andrew Deonarine,Derek S. Chan,Claire M. Connell,Edward W. Roberts,Qi Zhao,Otavia L. Caballero,Sarah A. Teichmann,Tobias Janowitz,Duncan I. Jodrell,David A. Tuveson,Douglas T. Fearon +14 more
TL;DR: A single protein, CXCL12, from a single stromal cell type, the FAP+ CAF, may direct tumor immune evasion in a model of human PDA, which permitted the analysis of why immunotherapy is ineffective in this human disease.
Journal ArticleDOI
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Daniel Öhlund,Daniel Öhlund,Daniel Öhlund,Abram Handly-Santana,Abram Handly-Santana,Giulia Biffi,Giulia Biffi,Ela Elyada,Ela Elyada,Ana S. Almeida,Ana S. Almeida,Mariano Ponz-Sarvise,Mariano Ponz-Sarvise,Mariano Ponz-Sarvise,Vincenzo Corbo,Tobiloba E. Oni,Tobiloba E. Oni,Tobiloba E. Oni,Stephen Hearn,Eun Jung Lee,Eun Jung Lee,Iok In Christine Chio,Iok In Christine Chio,Chang-Il Hwang,Chang-Il Hwang,Hervé Tiriac,Hervé Tiriac,Lindsey A. Baker,Lindsey A. Baker,Dannielle D. Engle,Dannielle D. Engle,Christine Feig,Anne Kultti,Mikala Egeblad,Douglas T. Fearon,James M. Crawford,Hans Clevers,Young-Kyu Park,Young-Kyu Park,David A. Tuveson,David A. Tuveson +40 more
TL;DR: Direct evidence for CAF heterogeneity in PDA tumor biology is provided, providing direct evidence for disease etiology and therapeutic development in mouse and human PDA tissue.